Cardiovascular

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heart beats (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).


A stroke occurs when the blood supply to part of the brain is interrupted. Patients with an irregular heart beat (known as atrial fibrillation) are at increased risk of stroke. Preventing stroke in these patients is a key focus of our cardiovascular team. Boehringer Ingelheim developed the first non-vitamin K antagonist oral anticoagulant (NOAC) to protect patients with non-valvular atrial fibrillation against stroke, advancing anticoagulation care.